Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ATR Is a Therapeutic Target in Synovial Sarcoma

16 Oct 2017

Abstract excerpt

Abstract Synovial sarcoma (SS) is an aggressive soft-tissue malignancy characterized by expression of SS18–SSX fusions, where treatment options are limited. To identify therapeutically actionable genetic dependencies in SS, we performed a series of parallel, high-throughput small interfering RNA (siRNA) screens and compared genetic dependencies in SS tumor cells with those in >130 non–SS tumor cell lines. This...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chromatin Remodeling and Cancer
Share to RNA Interference and Gene Delivery
Share to Sarcoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29038346
DOI: 10.1158/0008-5472.can-17-2056

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ATR Is a Therapeutic Target in Synovial SarcomaPMID 29038346Read ↗

Targeting of SUMOylation leads to cBAF complex stabilization and disruption of the SS18::SSX transcriptome in Synovial SarcomaSemantic proximity Read ↗

Targeting of SUMOylation leads to cBAF complex stabilization and disruption of the SS18::SSX transcriptome in Synovial SarcomaSemantic proximity Read ↗

Therapeutic Potential of Bromodomain and Extra-Terminal Domain Inhibitors for Synovial Sarcoma CellsSemantic proximity Read ↗

Molecular Profiling Defines Three Subtypes of Synovial SarcomaSemantic proximity Read ↗

SUMO2 Inhibition Reverses Aberrant Epigenetic Rewiring Driven by Synovial Sarcoma Fusion Oncoproteins and Impairs SarcomagenesisSemantic proximity Read ↗

Molecular and epigenetic oncogenesis in synovial sarcoma: implications for cancer biology, diagnosis and treatmentSemantic proximity Read ↗

Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcomaSemantic proximity Read ↗

Innovative Breakthroughs for the Treatment of Advanced and Metastatic Synovial SarcomaSemantic proximity Read ↗

DNA demethylating agents suppress preclinical models of synovial sarcomaSemantic proximity Read ↗

Opposing immune and genetic forces shape oncogenic programs in synovial sarcomaSemantic proximity Read ↗

Genetic and Molecular Heterogeneity of Synovial Sarcoma and Associated Challenges in TherapySemantic proximity Read ↗

Pharmacologic degradation of WDR5 suppresses oncogenic activities of SS18::SSX and provides a therapeutic of synovial sarcomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.